Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria
Comparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria
复制标题
DOI：
10.1016/j.trstmh.2010.05.009
复制
发表时间：
2010-10-01
影响因子：
2.2
通讯作者：
Adam, Ishag
中科院分区：
文献类型：
--
作者：
Eltahir, Hatim G.;Omer, Abubaker A.;Adam, Ishag
将66名患有不同表现的严重恶性疟原虫疟疾的苏丹Singa医院儿童随机分为两组（每组33名），分别在0、12和24小时静脉注射青蒿琥酯2-4 mg/kg，然后每天一次，或静脉注射奎宁20 mg/kg，然后10 mg/kg，每天三次。在发热、寄生虫清除和昏迷消退时间方面无显著差异。三名患者死亡，一名在青蒿琥酯组，两名在奎宁组。1例患者在奎宁输注后发生低血糖。因此，青蒿琥酯可用于治疗重症恶性疟疾。(C)2010年皇家热带医学和卫生学会。由爱思唯尔有限公司出版。保留所有权利。
Sixty-six children presenting to Singa hospital, Sudan with different manifestations of severe Plasmodium falciparum malaria were randomly divided into two well-matched groups (33 in each arm) to receive either intravenous artesunate 2-4 mg/kg at 0, 12, and 24 hours, then daily, or intravenous quinine 20 mg/kg initially then 10 mg/kg three times a day. There was no significant difference in the fever, parasite clearance, and coma resolution times. Three patients died, one in the artesunate and two in the quinine groups. One patient developed hypoglycaemia following quinine infusion. Thus, artesunate can be used for the treatment of severe falciparum malaria. (C) 2010 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.